On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression

Company: VistaGen Therapeutics Inc. (VTGN)
Category: Stock Spotlights

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues. For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction. VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression. Following completion of successful exploratory Phase 2A clinical development, the company is preparing to launch a planned Phase 2B clinical study of PH10 in major depressive disorder in early 2022. With its rapid-onset pharmacology, potential lack of systemic exposure and favorable safety results observed in all clinical studies to date, PH10 has potential to go beyond the current standard of care for depression as a novel stand-alone treatment for multiple depression disorders.”

To view the full article, visit https://nnw.fm/RVshQ

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://nnw.fm/VTGN

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217